Ranbaxy Launches NCE for Indian Dermatology market.
Ranbaxy Laboratories has launched a New Chemical Entity (NCE), Lulifin (Luliconazole), in the Indian Dermatology market.
This follows a strategic in-licensing agreement with Summit Pharmaceuticals International Corporation, Japan (SPI) allowing the former exclusive marketing rights for India. The introduction of this NCE strengthens Ranbaxy's presence in the dermatological segment.
- Share this article
- Got more on this story? Email PharmaAsia
- More About
- Drug Delivery
- Ranbaxy
- NCE
- Lulifin
- Indian
